

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Martin A. Reynolds, Melissa Grace, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Gregory Collins, Laura J. Brown, Jeffrey Geesin, Pamela L. Plouhar, Catherine W. Smith, and John Siekierka

Application No.: 10/630,227 Group Art Unit: 1647
Filed: July 30, 2003 Examiner: S.H. Shafer
Confirmation No.: 8291
Title: TRANS-CAPSULAR ADMINISTRATION OF HIGH SPECIFICITY CYTOKINE INHIBITORS INTO ORTHOPEDIC JOINTS

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

March 9, 2006

Date

Signature

Linda M. Byrnes

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[] under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

[] under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

[X] under 37 CFR 1.97(c) together with either:

[] a Statement under 37 CFR 1.97(e), as checked below, or

[X] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[] under 37 CFR 1.97(d) together with:

[] a Statement under 37 CFR 1.97(e), as checked below, and

[] a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application file.
(Filed after payment of issue fee)

03/15/2006 WABDELR1 00000014 10630227
01 FC:1805
180.00 DP

Statement Under 37 CFR 1.97(e)

- [] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- [] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- [] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- [X] Enclosed herewith is form PTO-1449:
 - [X] Copies of the cited references (B15-B20 and C39-C115) are enclosed.
 - [X] Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
 - [] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
 - [] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
 - [] The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - [] the explanation provided on the attached sheet.
 - [] the explanation provided in the Specification.
 - [] submission of the enclosed International Search Report.
 - [] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - [] the enclosed English language abstract.

[] Applicant requests that the following non-published pending applications be considered:
(Affix a label or apply the stamp "Non-Published IDS Reference - Do Not Scan" to the front of each unpublished pending appl'n.)

Examiner's
Initials

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

[] A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.

[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[X] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

Christine M. Doe

Registration No.: 58,073

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

March 9, 2006


PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3518.1015-000APPLICATION NO.
10/630,227SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT
IN AN APPLICATION

March 9, 2006

FIRST NAMED INVENTOR
Thomas M. DiMauroFILING DATE
July 30, 2003

(Use several sheets if necessary)

EXAMINER
S.H. ShaferCONFIRMATION NO.
8291GROUP
1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A22	5,510,370	04-23-1996	Hock
	A23	5,833,984	11-10-1998	Eibl, et al.
	A24	5,942,499	08-24-1999	Radomsky
	A25	6,340,369 B1	01-22-2002	Ferree
	A26	6,352,557 B1	03-05-2002	Ferree
	A27	6,554,830	04-29-2003	Chappius
	A28	6,590,081 B1	07-08-2003	Zhang
	A29	6,623,472 B1	09-23-2003	Reinecke, et al.
	A30	6,713,246 B1	03-30-2004	Reinecke, et al.
	A31	2001/0006948 A1	07-05-2001	Kang, et al.
	A32	2001/0026801 A1	10-04-2001	Tobinick
	A33	2002/0010471 A1	01-24-2002	Wironen, et al.
	A34	2002/0032155 A1	03-14-2002	Ferree
	A35	2002/0107200 A1	08-08-2002	Chang, et al.
	A36	2002/0198599 A1	12-26-2002	Haldimann
	A37	2003/0007972 A1	01-09-2003	Tobinick
	A38	2003/0069639 A1	04-10-2003	Sander, et al.
	A39	2003/0207827 A1	11-06-2003	Boyle, et al.
	A40	2004/0193274 A1	09-30-2004	Trieu
	A41	2004/0229786 A1	11-18-2004	Attawia, et al.
	A42	2005/0038001 A1	02-17-2005	Attawia, et al.
	A43	2003/0134792	07-17-2003	Pike, et al.
	A44	2002/0169162	11-14-2002	Smith, et al.

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE July 30, 2003
March 9, 2006 (Use several sheets if necessary)	EXAMINER S.H. Shafer	CONFIRMATION NO. 8291
		GROUP 1647

FOREIGN PATENT DOCUMENTS

EXAMINER _____ DATE CONSIDERED _____
GPO: 2011 OPM14-2 (GPO:2011-09026-24) 06/11/11

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE July 30, 2003	
March 9, 2006 (Use several sheets if necessary)		EXAMINER S.H. Shafer	CONFIRMATION NO. 8291	GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C39	Abstracts of the North American Spine Society 17 Annual Meeting, Montreal, Canada, October 29 through November 2, 2002, <i>The Spine Journal</i> 2(5 Suppl):49S-50S (2002).
C40	Ahn, N. U., <i>et al.</i> , "Effect of Nutrient Concentration and OP-1 on the Metabolism of Intervertebral Disc: In Vitro Organ Culture Study," 28, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C47	Alini, M. <i>et al.</i> , "A Biological Approach in Treating Disc Degeneration: Not for Today, but Maybe for Tomorrow," <i>European Spine Journal</i> , 11(Suppl 2):S215-S220 (2002).
C42	Allali, F. <i>et al.</i> , "Increase in Bone Mineral Density of Patients with Spondyloarthropathy Treated with Anti-Tumour Necrosis Factor α ," <i>Ann. Rheum. Dis.</i> , 62:347-349 (2003).
C43	Andonopoulos, A.P., <i>et al.</i> , "Intra-articular Anti-Tumor Necrosis Factor α Antibody in Recalcitrant Arthritis of Behçet's Disease," <i>Clinical and Experimental Rheumatology</i> 21(4 Suppl. 30):S57-58 (Jul-Aug. - 2003).
C44	Arai, I., <i>et al.</i> , "Pretreatment with Loxoprofen Sodium, 6-OHDA or Anti TNF-Alpha Antibody Reduce Fos-Like Immunoreactivity in Rat Experimental Lumbar Disc Herniation," 111, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C45	Ariga, K. <i>et al.</i> , "Mechanical Stress-Induced Apoptosis of Endplate Chondrocytes in Organ-Cultured Mouse Intervertebral Discs," <i>Spine</i> , 28(14):1528-1533 (2003).
C46	Biskobing, D.M., "Novel Therapies for Osteoporosis," <i>Expert Opinion Invest. Drugs</i> , 12(4):611-621 (2003).
C47	Bokarewa, M., <i>et al.</i> , "Local Infusion of Infliximab for the Treatment of Acute Joint Inflammation," <i>Ann. Rheum Dis</i> 62: 783-784 (2003).
C48	Burke, J. G., <i>et al.</i> , "Human Nucleus Pulposus Secretes Transforming Growth Factor Beta-1 and Basic Fibroblast Growth Factor," 189, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C49	Cardone, <i>et al.</i> , "Diagnostic and Therapeutic Injection of the Hip and Knee," <i>Family Medicine</i> , 67:2147-2152 (2003).
C50	Connolly, J., <i>et al.</i> , "Development of an Osteogenic Bone-Marrow Preparation," <i>The Journal of Bone and Joint Surgery, Inc.</i> , 71-A (5): 684-691 (1989).
C51	Conti, F., <i>et al.</i> , "Successful Treatment with Intraarticular Infliximab for Resistant Knee Monarthritis in a Patient with Spondylarthropathy," <i>Arthritis & Rheumatism</i> 52(4): 1224-1226 (April 2005).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227
		FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE July 30, 2003
March 9, 2006 (Use several sheets if necessary)		EXAMINER S.H. Shafer	CONFIRMATION NO. 8291
			GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C52	Cornefjord, M., et al., "Cerebrospinal Fluid Biomarkers in Experimental Spinal Nerve Root Injury," 38, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C53	Crandall, C., "Combination Treatment of Osteoporosis: A Clinical Review," <i>J. of Women's Health & Gender-Based Medicine</i> , 11(3):211-224 (2002).
C54	DeSantis, A. and Buchman, A., "Current and Emerging Therapies in Osteoporosis," <i>Expert Opin. Pharmacother.</i> , 3(7):835-843 (2002).
C55	Diwan, A. et al., "Current Concepts in Intervertebral Disk Restoration," <i>Tissue Engineering in Orthopedic Surgery</i> , 31(3):453-464 (2000).
C58	Edwards, S. L., et al., "Radiographic Assessment of Posteriorlateral Spine Fusion With and Without Platelet Rich Plasma," 117, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C57	Ezra, A., and Golomb, G., "Administration Routes and Delivery Systems of Bisphosphonates for the Treatment of Bone Resorption," <i>Adv. Drug Del. Rev.</i> , 42:175-195 (2000).
C58	Frain, J., et al., "Use of cDNA Microarrays to Investigate Cytokine Expression in Intervertebral Disc Degeneration," 126, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C59	Ganey, T. M. and Meisel, H. J., "A Potential Role for Cell-Based Therapeutics in the Treatment of Intervertebral Disc Herniation," <i>Eur. Spine J.</i> , 11 (Suppl. 2): S206-S214 (2002).
C60	Goodman, S. et al., "Effects of Local Infusion of TGF β on Bone Ingrowth in Rabbit Chambers," <i>J. Biomed. Mat. Res. (Appl Biomater)</i> , 53:475-479 (2000).
C61	Gouipple, P. et al., "Matrix Metalloproteinases: The Clue to Intervertebral Disc Degeneration?," <i>Spine</i> , 23(14): 1612-1626 (1998).
C62	Kawakami, et al., "Role of IL-8, MCP-1 and PH in Neuropathic Pain Enhanced by Degenerative Nucleus Pulposus," 127, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C63	Hunter, C. J., et al., "Functional Behavior of Notochordal Cell Clusters in the Canine Nucleus Pulposus: Cell Communication and Survival," 70, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3518.1015-000APPLICATION NO.
10/630,227SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT
IN AN APPLICATION

March 9, 2006

(Use several sheets if necessary)

FIRST NAMED INVENTOR
Thomas M. DiMauroFILING DATE
July 30, 2003EXAMINER
S.H. ShaferCONFIRMATION NO.
8291GROUP
1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C64	Hydrogels, Encyclopedia of Polymer Science and Technology, (Wiley and Sons, 2003).
C65	Imai, Y., et al., "Effect of Recombinant Human Osteogenic Protein-1 on Extracellular Matrix Metabolism by Human Annulus Fibrosus and Nucleus Pulposus Cells," 205, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C66	Imai, Y., et al., "The Quantification of Cytokine-Induced Matrix Catabolism in Tissue Engineered Intervertebral Discs," 67, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C67	Inui, Y., et al., "Fas-Ligand Expression on Nucleus Pulposus Cells Begins in Developing Embryo," 42, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C68	Karppinen, J., et al., "Tumor Necrosis Factor- α Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica," <i>Spine</i> , 28(8):750-754 (2003).
C69	Kato, H., et al., "The Effect of IL-1 on the Rabbit Intervertebral Disc In Vivo," 199, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C70	Kimble, R.B., et al., "Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis Via an InterLeukin-1 and Tumor Necrosis Factor-Mediated Stimulation of Macrophage Colony-Stimulating Factor Production," <i>J. Biol. Chem.</i> 271(46):28890-28897 (1996).
C71	Kimble, R.B., et al., "The Functional Block of TNF but Not of IL-6 Prevents Bone Loss in Ovariectomized Mice," <i>J. Bone Min. Res.</i> , 12(6):935-941 (1997).
C72	Koch, H., et al., "Spontaneous Secretion of Interleukin 1 Receptor Antagonist (IL-1Ra) by Cells Isolated from Herniated Lumbar Discal Tissue After Discectomy," <i>Cytokine</i> , 10(9): 703-705 (1998).
C73	Korhonen, T., et al., "Efficacy of Infliximab for Disc Herniation-Induced Sciatica One-Year Follow-Up," 14, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C74	Kozbor, D. and Roder, J.C., "The Production of Monoclonal Antibodies from Human Lymphocytes," <i>Immunol. Today</i> , 4(3):72-79 (1983).
C75	Kwon, U-H., et al., "Dexamethsone Stimulates Cellular Proliferation While Downregulates Matrix Synthesis in Intervertebral Disc Cells," 29, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227
March 9, 2006 (Use several sheets if necessary)		FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE July 30, 2003
		EXAMINER S.H. Shafer	CONFIRMATION NO. 8291
			GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C76	Lane, N.E., <i>et al.</i> , "Basic Fibroblast Growth Factor Forms New Trabeculae that Physically Connect with Pre-Existing Trabeculae, and This New Bone is Maintained with an Anti-Resorptive Agent and Enhanced with an Anabolic Agent in an Osteopenic Rat Model," <i>Osteoporos. Int.</i> , 14:374-382 (2003).
C77	La Van, <i>et al.</i> , "Small-scale Systems for <i>In Vivo</i> Drug Delivery," <i>Nature Biotechnology</i> 21: 1184-1191 (2003).
C78	Lehman, <i>et al.</i> , "Thalidomide Therapy for Recalcitrant Systemic Onset Juvenile Rheumatoid Arthritis," <i>J. Pediatrics</i> , 140: 125-7 (2002).
C79	Le Maitre, C. L., <i>et al.</i> , "Expression of the IL-1 Family in Human Intervertebral Disc," 217, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C80	Le Maitre, C. L., <i>et al.</i> , "Response of Human Intervertebral Disc Cells to IL-1," 216, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C81	Le Visage, C., <i>et al.</i> , "Interaction of Human Mesenchymal Stem Cells with Disc Cells: Changes in Biosynthesis of Extracellular Matrix," 25, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C82	Lee, C. S., <i>et al.</i> , "A Single Period of Hyperphysiologic Stretch Induces IL-6, TGF-beta and Cell Proliferation in Anulus Fibrosus Cells," 215, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C83	Li, J., <i>et al.</i> , "The Effects of Bone Morphogenetic Protein 2 (BMP-2) and Cartilage-Derived Morphogenic Protein 2 (CDMP-2) on Aggrecan Gene Expression in Chondrocytes," 30, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C84	Lotz, J. C., <i>et al.</i> , "Cytokines in Normal, Degenerated, and Nucleoplasty-Treated Porcine Discs," 157, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C85	Meijer, H., <i>et al.</i> , "The Production of Anti-Inflammatory Cytokines in Whole Blood by Physico-Chemical Induction," <i>Inflamm. Res.</i> , 52: 404-407 (2003).
C86	Miyamoto, H., <i>et al.</i> , "The Effect of Mechanical Stress on the Production of Inflammatory Agents by Disc Cells," 110, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C87	Molloy, <i>et al.</i> , "The Roles of Growth Factors in Tendon and Ligament Healing," <i>Sports. Med.</i> 33: 381-394 (2003).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227
March 9, 2006 (Use several sheets if necessary)		FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE July 30, 2003
		EXAMINER S.H. Shafer	CONFIRMATION NO. 8291
			GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C88	Müller, R. "Determination of Affinity and Specificity of Anti-Hapten Antibodies by Competitive Radioimmunoassay," <i>Meth. Enzymol.</i> , 92:589-601 (1983).
C89	Nakamura, K., <i>et al.</i> , "Local Application of Basic Fibroblast Growth Factor into the Bone Increases Bone Mass at the Applied Site in Rabbits," <i>Arch. Orthop. Trauma Surg.</i> , 115(6):344-346 (1996).
C90	Nakamura, K., <i>et al.</i> , "Stimulation of Endosteal Bone Formation by Local Intraosseous Application of Basic Fibroblast Growth Factor in Rats," <i>Rev. Rhum. [Engl. Ed.]</i> , 64(2):101-105 (1997).
C91	Nikas, S.N., <i>et al.</i> , "Treatment of Resistant Rheumatoid Arthritis by Intra-Articular Infliximab Injections: A Pilot Study," <i>Ann Rheum Dis</i> , 63: 102-103 (2004).
C92	Ohtori, S., <i>et al.</i> , "TNF- α and TNF- α Receptor 1 Upregulation in GLIA and Neurons After Nerve Injury. Studies in Murine DRG and Spinal Cord," 13, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C93	Ohtori, S., <i>et al.</i> , "TNF- α -Deficient Mice Have Fewer Macrophages in Injured Nerve and Reduced Glial Activation in DRG and Spinal Cord," 250, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C94	Okuma, M., <i>et al.</i> , "Rotary Cell Culture System Stimulates Annulus Fibrosus Cell Proliferation but Suppresses Proteoglycan Metabolism," 164, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C95	Pacifici, R., "Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis-The Second Decade," <i>Endocrinology</i> , 139(6):2659-2661 (1998).
C96	Pederson, A.W., <i>et al.</i> , "Thermal Assembly of a Biomimetic Mineral/Collagen Composite," <i>Biomaterials</i> , 24:4881-4890 (2003).
C97	Richardson, S., <i>et al.</i> , "Human Bone Marrow Mesenchymal Stromal Cells as a Source of Chondrocytes for Treatment of Intervertebral Disc Degeneration," 27, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C98	Risbud, M. V., <i>et al.</i> , "Mesenchymal Stem Cells Respond to Their Microenvironment In Vitro to Assume Nucleus Pulposus-Like Phenotype," 26, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C99	Rodan, G.A., <i>et al.</i> , "Therapeutic Approaches to Bone Diseases," <i>Science</i> , 289:1508-1514 (2000).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 9, 2006 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227
		FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE July 30, 2003
		EXAMINER S.H. Shafer	CONFIRMATION NO. 8291
			GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C100	Sakai, D., et al., "Autologous Transplantation of Mesenchymal Stem Cells for Disc Repair," 24, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C101	Sakai, D., et al., "Transplantation of Mesenchymal Stem Cells Embedded in Atelocollagen® Gel to the Intervertebral Disc: A Potential Therapeutic Model for Disc Degeneration," <i>Biomaterials</i> , 24: 3531-3541 (2003).
C102	Schattman, L., et al., "Treatment of Refractory Inflammatory Monoarthritis in Ankylosing Spondylitis by Intraarticular Injection of Infliximab," <i>The Journal of Rheumatology</i> , 33:1 82-85 (2006).
C103	Sobajima, S., et al., "Stem Cell Therapy for Degenerative Disc Disease: An In-Vitro Feasibility Study," 43, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C104	Stern, S., et al., "Human Intervertebral Disc Cell Culture for Disc Disorders," <i>Clin. Orthop.</i> , 419:238-244 (2004).
C105	Takada, T., et al., "IL-6 Production was Upregulated by Interaction Between Disc Tissue and Macrophages," 41, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C106	Takegami, K., et al., "Osteogenic Protein-1 Enhances Matrix Replenishment by Intervertebral Disc Cells Previously Exposed to Interleukin-1," <i>Spine</i> , 27(12):1318-1325 (2002).
C107	Tobinick, E.L. "Targeted Etanercept for Discogenic Neck Pain: Uncontrolled, Open-Label Results in Two Adults," <i>Clin. Thera.</i> , 25(4):1211-1218 (2003).
C108	Tsuji, T., et al., "Age-Related Changes in M-RNA Expression of Various Regulatory Factors in Rabbit Intervertebral Disc," 81, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C109	Vahle, J.L., et al., "Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety," <i>Toxicol. Pathol.</i> , 30(3):312-321 (2002).
C110	Weiler, C., et al., "Expression of TNF- α in Autopsy and Biopsy Specimens of Intervertebral Discs of Various Age and Degeneration," 233, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C111	Xie, X., et al., "Treatment of Spondylodiscitis Intravenous Versus Percutaneous Intradiscal Applications of Antibiotics: An Experimental Study in Rabbits," 120, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 9, 2006 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227
		FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE July 30, 2003
		EXAMINER S.H. Shafer	CONFIRMATION NO. 8291
			GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C112	Yabuki, S., <i>et al.</i> , "Prevention of Compartment Syndrome in Dorsal Root Ganglia Caused by Exposure to Nucleus Pulposus," <i>Spine</i> , 26(8):870-875 (2001).
C113	Yaffe, A., <i>et al.</i> , "Combined Local Application of Tetracycline and Bisphosphonate Reduces Alveolar Bone Resorption in Rats," <i>J. Periodontol.</i> , 74:1038-1042 (2003).
C114	Yoon, S. T., <i>et al.</i> , "LMP-1 Upregulates Proteoglycan Synthesis in Intervertebral Disc Cells Through a BMP Mediated Process," 31, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C115	http://arthritis.com/od/kneetreatments/g/viscosupplement_p.htm , 12-09-2005.

EXAMINER	DATE CONSIDERED
----------	-----------------